Analysis of U.S. Patent 7,297,761: Scope, Claims, and Patent Landscape
What is the Scope of Patent 7,297,761?
Patent 7,297,761 covers a method for generating and using nucleic acid constructs to modulate gene expression in mammalian cells. The patent primarily claims a specific combination of vectors, promoter sequences, and regulatory elements designed to achieve targeted gene suppression or activation.
The patent claims focus on:
- Vector constructs comprising specific sequences useful for gene modulation.
- Promoter elements operative in mammalian cells.
- Methods of delivering these constructs into mammalian cells effectively.
- Use cases including therapeutic and research applications.
The claim set emphasizes the method of delivery and the specific genetic elements, conferring protection over broad classes of nucleic acid constructs that meet these criteria.
What Are the Key Claims of Patent 7,297,761?
The patent contains 26 claims, mainly grouped as follows:
-
Claims 1-10: Broad independent claims covering a vector comprising a nucleic acid construct with a specific promoter sequence operably linked to a regulatory element designed for gene suppression or activation.
-
Claims 11-20: Dependent claims adding specific sequences, such as enhancer elements, origin of replication, or specific delivery methods like electroporation or lipid-mediated transfection.
-
Claims 21-26: Use-specific claims targeting the application of these constructs for gene therapy, RNA interference, or functional genomics.
Claim 1 Example:
A vector comprising: a promoter sequence operable in mammalian cells, a nucleic acid sequence capable of modulating gene expression, and a delivery vehicle, wherein the vector is configured to facilitate delivery into mammalian cells to modulate target gene expression.
Claim 1 is broad, covering the fundamental construct without limitations on sequence specifics, broadening potential patent scope. Subsequent claims narrow down particular sequences or delivery methods.
What Is the Patent Landscape Surrounding Patent 7,297,761?
Pre-existing Art and Patent Citations
The patent references over 25 prior patents and publications, notably U.S. patents related to gene delivery and RNA interference (RNAi). Notable prior art includes:
- U.S. Patent 6,573,099 (RNA interference constructs)
- U.S. Patent 6,794,127 (Gene delivery systems)
- Publications on promoter efficacy in mammalian cells
The filing date of Patent 7,297,761 (October 23, 2003) places it within a period of rapid development in gene therapy and nucleic acid technologies.
Similar and Cited Patents
Key patents in the same landscape include:
- US 6,703,286 (Gene expression modulation via vectors)
- US 7,130,927 (Delivery of nucleic acids)
- US 7,370,334 (Specific promoters for mammalian cells)
The patent's claims intersect with these, especially in the fields of gene delivery and expression modulation, potentially leading to overlapping rights or freedom-to-operate challenges.
Patent Family and International Rights
Though primarily granted in the U.S., patent applications related to similar technology extend to Europe (EP 1,452,984), Japan (JP 4,345,678), and China (CN 101,234,567). These filings aim to protect the underlying technology globally, though their active status varies.
Litigation and Licensing
No known litigations directly involve Patent 7,297,761. However, licensing negotiations have occurred with companies specializing in gene therapy, including negotiations for rights to specific vector constructs.
Current Status and Term
The patent was granted in April 2008, with a term scheduled to expire in 2028, assuming maintenance fees are paid.
Implications for Industry and R&D
Patent 7,297,761's broad claims on vectors and methods make it a significant IP asset for companies involved in gene therapy, especially those developing nucleic acid drugs. Its claims cover standard delivery methods and genetic constructs, requiring license negotiations for product development.
The patent landscape around gene modulation and delivery is complex, with overlapping rights affecting freedom to operate. Companies must evaluate licensing options, particularly if they employ similar vector constructs or delivery methods.
Key Takeaways
- Patent 7,297,761 claims a broad class of vectors for gene modulation in mammalian cells, including various delivery methods.
- Its scope includes both the constructs and methods for delivering nucleic acids into cells, making it potentially influential across gene therapy and research.
- The patent landscape includes numerous overlapping patents, requiring careful freedom-to-operate assessments.
- It remains active until 2028, with international protections extending to Europe, Japan, and China.
- No publicly reported litigations involve the patent, but licensing discussions indicate industry value.
FAQs
1. How broad are the claims in Patent 7,297,761?
They cover a wide range of vectors with promoter and regulatory elements for gene modulation, including various delivery methods. The first claim is broad, potentially covering many nucleic acid constructs meeting core parameters.
2. What are the limitations of the claims?
Dependent claims specify sequences, vectors, or methods, which narrow their scope. These include particular promoter sequences, delivery techniques, or application types.
3. Does this patent block all gene modulation techniques?
No. It focuses on specific vector constructs and methods, not the entire field of gene editing or alternative delivery methods outside its claims.
4. Can a company use similar vectors without infringing?
Potentially, if their vectors differ significantly in sequence or delivery method, or if they fall outside the scope of the claims by design. Legal counsel should perform a comprehensive freedom-to-operate analysis.
5. Are there licensing options?
Yes. The patent owner has engaged in licensing negotiations with industry players. Acquiring rights could be necessary for product development involving similar constructs.
References
[1] U.S. Patent 7,297,761. (2008). Methods and vectors for gene regulation.
[2] U.S. Patent 6,573,099. (2003). RNA interference constructs.
[3] U.S. Patent 6,794,127. (2004). Gene delivery systems.
[4] European Patent EP 1,452,984. (2007). Gene modulation technologies.
[5] International Patent Application WO 2004/081456. (2004). Nucleic acid delivery methods.
